Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Galunisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 known ✓ | P36897 | 19/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | TGFB2 | P61812 | 1/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 1.00 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 1.00 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 5/20 | 0.71 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galunisertib SCHEMBL12922153 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14KDRGAKRIPK2 | |
| Galunisertib SCHEMBL29438525 | 0.99 | TGFBR1 (0.98) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL29773207 | 0.97 | TGFBR1 (0.95) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL3360014 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL15678350 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL414159 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL21702385 | 0.91 | TGFBR1 (0.84) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL373341 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL16695915 | 0.89 | TGFBR1 (0.81) | TGFBR1MAPK14KDRGAKRIPK2 | |
| SCHEMBL18347825 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14KDRGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2036 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104985-A1 | TGF-BETA RECEPTOR INHIBITORS FOR USE IN THE THERAPEUTIC TREATMENT OF A PULMONARY FIBROTIC DISEASE | A.D.A. S.R.L. (IT) | 2026-05-21 | — | — | WO | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| CN-122038299-A | Induction medium for transdifferentiating cells into dopaminergic neuron source exosomes by using small molecular compound in vitro induction, culture method and application | 广西壮族自治区人民医院 | 2026-05-15 | — | — | CN | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108496-A1 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260092257-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2026-04-02 | — | — | US | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| US-12560591-B2 | Methods of treatment with CD8 T cell-mediated immune therapy | PROVIDENCE HEALTH & SERVICES—OREGON (US) | 2026-02-24 | — | — | US | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| US-20220089566-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | claimed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | claimed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | claimed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | claimed |
| US-11279915-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | MAINE MEDICAL CENTER RESEARCH INSTITUTE (US) | 2022-03-22 | — | — | US | claimed |
| WO-2022051847-A1 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-17 | — | — | WO | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |